2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-Y0470
    Semicarbazide hydrochloride 563-41-7 ≥98.0%
    Semicarbazide hydrochloride is an orally active urea derivative. Semicarbazide hydrochloride binds to copper or iron in cells. Semicarbazide hydrochloride inhibits the activity of soluble semicarbazide sensitive amine oxidase (SSAO). Semicarbazide hydrochloride damages cartilage, blood vessels, ovaries, testicles, and thyroid follicles.
    Semicarbazide hydrochloride
  • HY-101259
    BMS-195614 182135-66-6 ≥99.0%
    BMS-195614 (BMS 614) is an orally active neutral RARα-selective antagonist with a Ki of 2.5 nM. BMS-195614 restores the expression of Bcl2. BMS-195614 inhibits the transactivation of NF-κB, AP-1 and PPAR. BMS-195614 downregulates the expression of IL-6 and VEGF. BMS-195614 reduces blue light-induced phototoxicity and inhibits cell migration. BMS-195614 modulates inflammation and angiogenesis.
    BMS-195614
  • HY-107635
    TMN355 1186372-20-2 99.67%
    TMN355 is a potent chemical cyclophilin A inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis.
    TMN355
  • HY-108575
    Chromanol 293B 163163-23-3 ≥99.0%
    Chromanol 293B is a selective blocker of the slow delayed rectifier K+ current (IKs) with IC50 of 1-10 μM and a weak inhibitor of KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC50 of 19 μM.
    Chromanol 293B
  • HY-113289
    Brassicasterol 474-67-9 99.92%
    Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC50=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease.
    Brassicasterol
  • HY-120855
    CCG-100602 1207113-88-9 99.29%
    CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF.
    CCG-100602
  • HY-122697
    ML418 1928763-08-9 99.78%
    ML418 is a potent, selective and CNS penetrating Kir7.1 potassium channel blocker. ML418 inhibits Kir7.1 with an IC50 value of 0.31 μM. ML418 can be used for the research of neurological, cardiovascular, endocrine and muscle disorders.
    ML418
  • HY-124702
    ICA-105574 316146-57-3 99.25%
    ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC50 value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently.
    ICA-105574
  • HY-128741
    D-Allose 2595-97-3 99.85%
    D-Allose exhibits antitumor activity against various cancer cells. D-Allose scavenges reactive oxygen species (ROS) and reduces oxidative stress damage. D-Allose exhibits anti-inflammatory and neuroprotective through inhibition of TLR4/PI3K/AKT signaling pathway. D-Allose exhibits antihypertensive, cryoprotective, and anti-osteoporotic activities.
    D-Allose
  • HY-128747
    α-D-Glucose-1-phosphate disodium 56401-20-8 99.93%
    α-D-Glucose-1-phosphate disodium is used as a starting material for synthesis of glucuronic acid. α-D-Glucose-1-phosphate disodium can be used as a cytostatic compound essential for cardiopathic therapy, as an antibiotic, as an immunosuppressive agent, and as a circulatory system therapy element.
    α-D-Glucose-1-phosphate disodium
  • HY-130494
    (±)11(12)-EET 87173-81-7 ≥98.0%
    (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.
    (±)11(12)-EET
  • HY-136744
    Caspase-9 Inhibitor III 403848-57-7 99.00%
    Caspase-9 Inhibitor III (Ac-LEHD-cmk) is a caspase-9 inhibitor. Caspase-9 Inhibitor III exhibits protective effects on ischemia-reperfusion-induced myocardial injury.
    Caspase-9 Inhibitor III
  • HY-141510
    myo-Inositol trispyrophosphate hexasodium 23103-35-7
    myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer.
    myo-Inositol trispyrophosphate hexasodium
  • HY-149120
    ASM-IN-1 2913151-46-7 98.65%
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity.
    ASM-IN-1
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    GalNAc unconjugated/naked Inclisiran
  • HY-17495A
    Carteolol hydrochloride 51781-21-6 99.96%
    Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.
    Carteolol hydrochloride
  • HY-70057A
    Safinamide mesylate 202825-46-5 99.07%
    Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 nM). Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8?μM) than at resting (IC50=262?μM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al.
    Safinamide mesylate
  • HY-B0130A
    Perindopril erbumine 107133-36-8 99.98%
    Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
    Perindopril erbumine
  • HY-B0231A
    Enalaprilat 76420-72-9 99.76%
    Enalaprilat (MK-422 anhydrous), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat can be used for the research of hypertension.
    Enalaprilat
  • HY-B0653A
    Levobupivacaine hydrochloride 27262-48-2 99.86%
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity